Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloromethane SCHEMBL3323025 | 0.95 | CHRNA7 (0.48) | CHRNA7SCN5ASCN2ASCN10ANPC1 | |
| SCHEMBL3612891 | 0.89 | PTPN1 (0.51) | CHRNA7NPC1MAPTSMN1; SMN2 | |
| SCHEMBL3327081 | 0.88 | NPC1 (0.50) | CHRNA7SCN5ASCN2ASCN10ANPC1 | |
| SCHEMBL3325793 | 0.88 | SCN5A (0.58) | CHRNA7SCN5ASCN2ASCN10ANPC1 | |
| SCHEMBL373086 | 0.87 | CHRNA7 (0.58) | CHRNA7NPC1PDE4BPDE4DMAPT | |
| Hydrochloric Acid SCHEMBL3328099 | 0.86 | SCN5A (0.57) | CHRNA7SCN5ASCN2ASCN10ANPC1 | |
| SCHEMBL3326108 | 0.86 | CHRNA7 (0.51) | CHRNA7PDE5APDE4BMAPT | |
| SCHEMBL4702386 | 0.85 | CHRNA7 (0.52) | CHRNA7SCN5ASCN2ASCN10ANPC1 | |
| SCHEMBL3618966 | 0.83 | CHRNA7 (0.51) | CHRNA7SCN5ASCN2ASCN10ANPC1 | |
| SCHEMBL3326650 | 0.83 | ALDH1A1 (0.61) | CHRNA7NPC1PDE5APDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130483-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | US | claimed |
| EP-1599476-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH AS (DK) | 2009-10-14 | — | — | EP | claimed |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | NEUROSEARCH A/S (DK) | 2006-07-06 | — | — | US | claimed |
| EP-1599476-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-11-30 | — | — | EP | claimed |
| WO-2004076453-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2004-09-10 | — | — | WO | claimed |
| EP-1713810-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | disclosed |
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PETERS DAN | 2010-05-27 | — | — | US | disclosed |
| US-20100130483-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | US | disclosed |
| US-7678788-B2 | Diazabicyclic aryl derivatives | NEUROSEARCH A/S (DK) | 2010-03-16 | — | — | US | disclosed |
| EP-1599476-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH AS (DK) | 2009-10-14 | — | — | EP | disclosed |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | disclosed |
| EP-1713810-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | disclosed |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | NEUROSEARCH A/S (DK) | 2006-07-06 | — | — | US | disclosed |
| EP-1599476-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005075482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | disclosed |
| WO-2004076453-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130483-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES | CHRNA6, CHRNA10, CHRNA2 | CHRNA7 6/4885SCN5A 1076/4885SCN2A 668/4885 |
| US-20060148789-A1 | Novel diazabicyclic aryl derivatives | CHRNA6, CHRNA10, CHRNA2 | CHRNA7 6/4885SCN5A 1076/4885SCN2A 668/4885 |
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA6, CHRNA10, CHRNA2 | CHRNA7 5/4885SCN5A 911/4885SCN2A 589/4885 |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | CHRNA6, CHRNA10, CHRNA2 | CHRNA7 5/4885SCN5A 911/4885SCN2A 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.